Jaguar Animal Health, Inc. (NASDAQ:JAGX) Sees Significant Increase in Short Interest

Jaguar Animal Health, Inc. (NASDAQ:JAGX) was the target of a significant growth in short interest in the month of January. As of January 15th, there was short interest totaling 552,389 shares, a growth of 99.4% from the December 31st total of 277,020 shares. Currently, 16.0% of the company’s stock are sold short. Based on an average daily trading volume, of 3,207,496 shares, the days-to-cover ratio is currently 0.2 days. Based on an average daily trading volume, of 3,207,496 shares, the days-to-cover ratio is currently 0.2 days. Currently, 16.0% of the company’s stock are sold short.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on JAGX. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jaguar Animal Health in a research report on Thursday, January 22nd. Wall Street Zen cut shares of Jaguar Animal Health to a “strong sell” rating in a report on Friday, January 23rd. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Jaguar Animal Health has an average rating of “Hold” and a consensus price target of $60.00.

Jaguar Animal Health Stock Performance

Shares of JAGX stock opened at $0.67 on Friday. The company has a market capitalization of $2.52 million, a price-to-earnings ratio of -0.02 and a beta of -0.42. The company has a debt-to-equity ratio of 4.08, a quick ratio of 0.52 and a current ratio of 0.81. Jaguar Animal Health has a one year low of $0.64 and a one year high of $25.75. The company’s 50-day moving average is $1.05 and its 200 day moving average is $1.67.

Jaguar Animal Health (NASDAQ:JAGX) last issued its earnings results on Friday, November 14th. The biotechnology company reported ($6.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.08) by ($1.20). Jaguar Animal Health had a negative return on equity of 1,194.94% and a negative net margin of 341.90%.The firm had revenue of $3.08 million during the quarter, compared to analysts’ expectations of $3.73 million. Sell-side analysts expect that Jaguar Animal Health will post -0.8 EPS for the current fiscal year.

Jaguar Animal Health Company Profile

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.